QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS5-Region Domestic Shipping
What is Tirzepatide??
Tirzepatide (LY3298176, CAS 2023788-19-2) is a 39-amino acid synthetic twincretin that simultaneously activates both the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) — a mechanism distinct from pure GLP-1 analogs (semaglutide, liraglutide). Developed by Eli Lilly, Tirzepatide incorporates a C18 fatty diacid for albumin binding (~5-day half-life) at lysine-26. In preclinical and clinical research it produces additive to synergistic reductions in HbA1c, body weight, and fasting glucose vs. GLP-1R-only agonists, with mechanistic interest in the GIP arm’s contribution to energy expenditure, adipose lipolysis, and glucagon regulation.
Research Applications
Dual GIP/GLP-1 Receptor Biology
GIPR vs. GLP-1R signalling contributions, Gs/cAMP/PKA, β-arrestin recruitment, receptor cross-talk
Glucose Homeostasis
Insulin secretion potentiation (GIP+GLP-1), glucagon suppression, hepatic glucose output
Obesity & Weight Loss
Hypothalamic appetite regulation, adipose lipolysis, energy expenditure mechanisms
Metabolic Syndrome
Lipid profile, insulin resistance, NAFLD/NASH models, cardiovascular risk factor research
Mechanism vs. GLP-1 Monotherapy
Tirzepatide vs. semaglutide: GIP arm contribution to weight loss and β-cell preservation
Quick Specs
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC — every batch |
| CAS Number | 2023788-19-2 |
| Also Known As | LY3298176, Mounjaro® active peptide |
| Molecular Weight | ~4813 Da |
| Half-Life | ~5 days (C18 fatty diacid albumin binding) |
| Peptide Type | Synthetic dual GIP/GLP-1 receptor agonist — twincretin |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house Fmoc SPPS — Qingdao, China |
| Storage | -20°C sealed | 2–8°C reconstituted (2–4 weeks) |
| Shelf Life | 24 months unopened |
